Released Jul 31, 2024, after the close
10-Q filed Aug 6, 2024, 37 days after period end · 0000950170-24-091888
Q2 2024 · 10-Q
Revenue$22.49M$22.49M −18.7% vs Q2 2023−50.6% vs Q1 2024
Net Income-$45.72M-$45.72M N/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$0.12-$0.12 N/M vs Q2 2023N/M vs Q1 2024
Gross Profit$10,374,000−23.7%
Operating Income-$30,261,000N/M
Operating Cash Flowderived-$39,050,000N/M
Free Cash Flowderived-$40,987,000N/M
Margins · derived
Gross margin46.1%−3.0 pt vs Q2 2023
Operating margin-134.5%−71.5 pt vs Q2 2023
Net margin-203.3%−141.7 pt vs Q2 2023
What the release said
The release
Same quarter
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | $22.49M | $27.67M | $18.78M | $31.02M |
| Net Income | -$45.72M | -$17.04M | -$63.54M | -$17.14M |
| EPS Diluted | -$0.12 | -$0.22 | -$0.82 | -$0.23 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR